Alzheimer's Disease Clinical Trial Landscape
Data updated: May 20, 2026
1,507 clinical trials tracked since 2008
Alzheimer's Disease is a progressive neurodegenerative condition and the most common cause of dementia, primarily affecting older adults and characterized by cognitive decline. The clinical trial landscape for Alzheimer's Disease demonstrates substantial research activity, with 1,498 trials registered since 2008, and 367 trials currently active. The majority of active trials are in Phase 2 (199 trials), followed by Phase 1 (105 trials), suggesting a strong focus on early-stage therapeutic development. Phase 3 trials account for 84 active trials, while Phase 4 has 35. Eli Lilly leads industry sponsorship of active trials with 10, followed by Bristol-Myers Squibb with 8, Roche with 6, Luye Pharma Group Ltd. with 5, and ACADIA Pharmaceuticals Inc. with 4. The high number of Phase 2 trials relative to Phase 3 suggests a pipeline still heavily invested in exploring novel therapeutic approaches.
372 active
/
1507 total (since 2008)
105
Phase 1 Active
516 total
202
Phase 2 Active
718 total
86
Phase 3 Active
288 total
35
Phase 4 Active
137 total
Top Industry Sponsors
Sorted by active Active Done Failed
Eli Lilly 12 26 6
Bristol-Myers Squibb 8 11 1
Roche 6 20 10
ACADIA Pharmaceuticals Inc. 4 3 1
Luye Pharma Group Ltd. 4 1 0
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT06709014 ACTIVE NOT RECRUITING
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
Annovis Bio Inc. n=760
NCT05980949 RECRUITING
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company n=800
NCT06126224 RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company n=500
NCT06947941 RECRUITING
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
Bristol-Myers Squibb n=325
NCT05508789 ACTIVE NOT RECRUITING
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
Eli Lilly and Company n=1,500
+ 283 more Phase 3 trials — see full database below
Alzheimer's Disease — Trials Started by Year (last 10 years)
2016 74
2017 79
2018 79
2019 78
2020 66
2021 89
2022 92
2023 81
2024 96
2025 103
2026 55
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Eli Lilly 44
Bristol-Myers Squibb 20
Roche 36
ACADIA Pharmaceuticals Inc. 8
Luye Pharma Group Ltd. 5
Karuna Therapeutics, Inc., a Bristol Myers Squibb company 4
Eisai Inc. 16
Green Valley (Shanghai) Pharmaceuticals Co., Ltd. 4
Regeneration Biomedical, Inc. 3
Merck 27
Active Trials by Phase
Phase 1 105
Phase 2 202
Phase 3 86
Phase 4 35
Enrollment Size Distribution
1-50 617
51-200 511
201-500 212
501-1k 71
1k+ 54
All Industry Sponsors
Sorted by active Active Done Failed
Eli Lilly 12 26 6
Bristol-Myers Squibb 8 11 1
Roche 6 20 10
ACADIA Pharmaceuticals Inc. 4 3 1
Luye Pharma Group Ltd. 4 1 0
Karuna Therapeutics, Inc., a Bristol Myers Squibb company 4 0 0
Eisai Inc. 3 11 2
Green Valley (Shanghai) Pharmaceuticals Co., Ltd. 3 0 1
Regeneration Biomedical, Inc. 3 0 0
Merck 2 18 7
Novartis 2 17 4
GSK 2 10 4
Intra-Cellular Therapies, Inc. 2 1 1
Denali Therapeutics Inc. 2 1 0
NKGen Biotech, Inc. 2 0 1
NCT06709014 ACTIVE NOT RECRUITING
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
Annovis Bio Inc. n=760
NCT07583979 NOT YET RECRUITING
Electroacupuncture for Cognitive Toxicity in Cancer Survivors: Assessing Implementation, Cost, and Effectiveness for Integration
National Cancer Centre, Singapore n=168
NCT07084831 NOT YET RECRUITING
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
European Group for Research In Schizophrenia n=171
NCT05980949 RECRUITING
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company n=800
NCT06126224 RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company n=500
NCT06947941 RECRUITING
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
Bristol-Myers Squibb n=325
NCT05508789 ACTIVE NOT RECRUITING
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
Eli Lilly and Company n=1,500
NCT07170150 RECRUITING
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Hoffmann-La Roche n=800
NCT06937229 RECRUITING
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Bristol-Myers Squibb n=600
NCT06976216 RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Bristol-Myers Squibb n=586
NCT07571161 NOT YET RECRUITING
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
Eli Lilly and Company n=140
NCT07177352 RECRUITING
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Hoffmann-La Roche n=13,000
NCT06194799 ENROLLING BY INVITATION
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
ACADIA Pharmaceuticals Inc. n=752
NCT05511363 RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company n=410
NCT07169578 RECRUITING
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Hoffmann-La Roche n=800
NCT06976203 RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Bristol-Myers Squibb n=586
NCT05230758 RECRUITING
Effect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour
Donald Mabbott n=140
NCT07011745 RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
Bristol-Myers Squibb n=352
NCT06585787 RECRUITING
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company n=406
NCT07011732 RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Bristol-Myers Squibb n=352
NCT05641688 RECRUITING
[18F]PI-2620 Phase 3 Histopathological Study
Life Molecular Imaging Ltd n=200
NCT06125951 ACTIVE NOT RECRUITING
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
Actinogen Medical n=247
NCT07095465 ENROLLING BY INVITATION
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc. n=126
NCT04570085 RECRUITING
Effect of CAFfeine on Cognition in Alzheimer's Disease
University Hospital, Lille n=248
NCT07284472 RECRUITING
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
Exciva GmbH n=300
NCT06159673 RECRUITING
ACP-204 in Adults With Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc. n=1,074
NCT03887455 ACTIVE NOT RECRUITING
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
Eisai Inc. n=1,906
NCT04098666 ACTIVE NOT RECRUITING
Metformin in Alzheimer's Dementia Prevention
Columbia University n=326
NCT07284316 ACTIVE NOT RECRUITING
Effect of a Multidomain Intervention Plus Turmeric on the Prevention of Cognitive Decline in People Over 55 Years of Age With Insulin Resistance.
Instituto Mexicano del Seguro Social n=100
NCT03804229 ACTIVE NOT RECRUITING
Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia
Capital Medical University n=707
NCT04468659 ACTIVE NOT RECRUITING
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Eisai Inc. n=1,400
NCT06384573 ACTIVE NOT RECRUITING
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
Washington University School of Medicine n=40
NCT07083154 RECRUITING
GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School n=420
NCT07422311 NOT YET RECRUITING
To Evaluate the Efficacy, Safety, and Tolerability of Dronabinol Oral Solution for Agitation in Patients With Alzheimer's Disease
Benuvia Therapeutics Inc. n=140
NCT05303701 NOT YET RECRUITING
GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
Samsung Pharmaceutical Co., Ltd. n=750
NCT07422857 RECRUITING
Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function
JYAMS PET Research & Development Limited n=316
NCT04661280 RECRUITING
Donepezil Versus Non-drug Treatment in Alzheimer's Disease.
Assistance Publique - Hôpitaux de Paris n=240
NCT06647498 RECRUITING
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Washington University School of Medicine n=280
NCT05269394 ACTIVE NOT RECRUITING
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
Washington University School of Medicine n=197
NCT05552157 RECRUITING
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Washington University School of Medicine n=280
NCT01760005 ACTIVE NOT RECRUITING
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
Washington University School of Medicine n=490
NCT07142954 RECRUITING
Epidemiology and Biomarker Study in Alzheimer's Disease
Eli Lilly and Company n=3,400
NCT07062198 RECRUITING
Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease
ScandiBio Therapeutics AB n=845
NCT04516057 RECRUITING
Nabilone for Agitation Blinded Intervention Trial
Sunnybrook Health Sciences Centre n=112
NCT03860857 RECRUITING
Biomarker Exploration in Aging, Cognition and Neurodegeneration
University of California, Irvine n=300
NCT05026866 ACTIVE NOT RECRUITING
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Eli Lilly and Company n=2,996
NCT05397639 RECRUITING
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
Suven Life Sciences Limited n=375
NCT07234695 RECRUITING
LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau n=120
NCT05470816 ACTIVE NOT RECRUITING
Tranexamic Acid to Reduce Delirium After Gastrointestinal Surgery: the TRIGS-D Trial
Bayside Health n=826
NCT06534723 RECRUITING
Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)
Sichuan Jishengtang Pharmaceutical Co., Ltd. n=570
NCT06797817 NOT YET RECRUITING
Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain
Universidad de Almeria n=156
NCT07251023 RECRUITING
Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia
Bigespas LTD n=450
NCT05809908 NOT YET RECRUITING
Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study
Cerecin n=535
NCT06653153 ACTIVE NOT RECRUITING
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Eli Lilly and Company n=1,400
NCT05738486 ACTIVE NOT RECRUITING
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
Eli Lilly and Company n=1,175
NCT05532657 ACTIVE NOT RECRUITING
ACHIEVE Brain Health Follow-Up Study
Johns Hopkins University n=629
NCT05456503 RECRUITING
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
University of Pennsylvania n=72
NCT06304883 ACTIVE NOT RECRUITING
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
Alzheon Inc. n=163
NCT05531526 ACTIVE NOT RECRUITING
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
AriBio Co., Ltd. n=1,535
NCT03121209 ACTIVE NOT RECRUITING
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial - Hemodynamics (CREST-H)
Columbia University n=385
NCT06191965 RECRUITING
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
Mclean Hospital n=100
NCT04437511 ACTIVE NOT RECRUITING
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Eli Lilly and Company n=1,736
NCT06950190 ENROLLING BY INVITATION
Evaluating Cognitive Changes on Patients in Chemotherapy (ECCPC)
Ellis Medicine n=100
NCT07115238 RECRUITING
Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD
Sinotau Pharmaceutical Group n=354
NCT06996730 NOT YET RECRUITING
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
Banner Health n=240
NCT06254469 RECRUITING
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
CereMark Pharma, LLC n=230
NCT07066826 NOT YET RECRUITING
Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
Wanbangde Pharmaceutical Group Co., LTD n=720
NCT07060391 NOT YET RECRUITING
A Prospective Multicenter RCT Study of Deep Jugular Lymphovenous Anastomosis in the Treatment of Alzheimer's Disease
Shanghai Jiao Tong University School of Medicine n=186
NCT06566183 NOT YET RECRUITING
International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Left Ventricular Dysfunction Trial
NYU Langone Health n=1,200
NCT05983575 ACTIVE NOT RECRUITING
A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease
Sound Wave Innovation CO., LTD. n=220
NCT06964230 NOT YET RECRUITING
A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects
T3D Therapeutics, Inc. n=376
NCT05463731 ACTIVE NOT RECRUITING
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Eli Lilly and Company n=1,667
NCT06120049 RECRUITING
[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
prof. dr. Koen Van Laere n=113
NCT03108846 ACTIVE NOT RECRUITING
Escitalopram for Agitation in Alzheimer's Disease
JHSPH Center for Clinical Trials n=187
NCT06702124 RECRUITING
A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease
I.R.C.C.S. Fondazione Santa Lucia n=348
NCT06530732 RECRUITING
Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study)
Zhejiang Provincial People's Hospital n=60
NCT03848312 RECRUITING
Preventing Alzheimer's With Cognitive Training
University of South Florida n=7,600
NCT06514066 NOT YET RECRUITING
Cannabidiol's Role in Dementia Management
Hospital Pengajar Universiti Putra Malaysia n=486
NCT05267535 ACTIVE NOT RECRUITING
Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease
Neurim Pharmaceuticals Ltd. n=225
NCT03116126 ACTIVE NOT RECRUITING
Noradrenergic Add-on Therapy With Guanfacine
Imperial College London n=148
NCT05976152 RECRUITING
Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER)
Fudan University n=3,200
NCT05143528 NOT YET RECRUITING
Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease
KeifeRx, LLC n=1,275
NCT04777396 COMPLETED
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
Novo Nordisk A/S n=1,840
NCT05891496 COMPLETED
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
Novo Nordisk A/S n=23
NCT06736509 TERMINATED
An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study
Axsome Therapeutics, Inc. n=139
NCT05894954 COMPLETED
Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment
Alzheimer's Prevention and Reversal Project, Inc. n=73
NCT03789760 COMPLETED
The Clinical Trial of Chinese Herbal Medicine (SaiLuoTong) Capsule
Shineway Pharmaceutical Co.,Ltd n=493
NCT04374136 TERMINATED
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
Alector Inc. n=119
NCT05271552 COMPLETED
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)
BioXcel Therapeutics Inc n=151
NCT04947553 COMPLETED
A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation
Axsome Therapeutics, Inc. n=456
NCT05557409 COMPLETED
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
Axsome Therapeutics, Inc. n=408
NCT04770220 COMPLETED
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
Alzheon Inc. n=325
NCT02446132 TERMINATED
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=1,197
NCT05026177 TERMINATED
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
Cassava Sciences, Inc. n=1,125
NCT05542953 COMPLETED
[18F]APN-1607 PET in Subjects With AD Compared to HC
APRINOIA Therapeutics n=230
NCT03446001 COMPLETED
Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment
TauRx Therapeutics Ltd n=598
NCT05256134 TERMINATED
A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)
Hoffmann-La Roche n=25
NCT04408755 TERMINATED
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=184
NCT04464564 TERMINATED
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=241
NCT04994483 COMPLETED
Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease
Cassava Sciences, Inc. n=804
NCT05575076 TERMINATED
Open-label Extension for Phase 3 Clinical Trials of Simufilam
Cassava Sciences, Inc. n=1,081
NCT05686044 COMPLETED
A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD
Annovis Bio Inc. n=351
NCT02360215 COMPLETED
Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases
NRG Oncology n=518
NCT05310071 TERMINATED
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
Biogen n=1,027
NCT04886063 TERMINATED
Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
LeonaBio n=423
NCT01447719 COMPLETED
Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07
Avid Radiopharmaceuticals n=110
NCT03554265 COMPLETED
Brain and Gut Plasticity in Mild TBI or Post-acute COVID Syndrome Following Growth Hormone Therapy
The University of Texas Medical Branch, Galveston n=72
NCT04241068 TERMINATED
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
Biogen n=1,696
NCT06424236 TERMINATED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation
Washington University School of Medicine n=73
NCT05432206 COMPLETED
MEDical CANnabis for Improving Symptoms During Severe DEMentia Disorders in Long-term Care Facility in Geneva
Fondation pour l'accueil et l'hébérement des personnes âgées n=27
NCT05749939 COMPLETED
Acceptance Commitment Therapy for Caregivers of People with Memory Loss
Utah State University n=121
NCT05108922 COMPLETED
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
Eli Lilly and Company n=148
NCT02719327 COMPLETED
Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid
VA Office of Research and Development n=131
NCT01767909 COMPLETED
The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)
University of Southern California n=240
NCT03393520 COMPLETED
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=601
NCT03620981 COMPLETED
Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Co., Ltd. n=410
NCT04552041 COMPLETED
Prospekta in the Treatment of Cognitive, Behavioral and Psychiatric Disorders in Patients With Vascular Dementia.
Materia Medica Holding n=406
NCT04771299 TERMINATED
Assessing the Role of Cariprazine in Improving Cognition in Euthymic Bipolar Patients
Lakshmi N Yatham n=1
NCT03724942 COMPLETED
Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Co., Ltd. n=164
NCT04395339 TERMINATED
GM1 Prophylaxis for WBRT Related Cognitive Dysfunction
Sun Yat-sen University n=51
NCT05239663 TERMINATED
GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer
Sun Yat-sen University n=76
NCT03486938 COMPLETED
Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease
AgeneBio n=164
NCT04374253 TERMINATED
A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)
Hoffmann-La Roche n=1,382
NCT03444870 TERMINATED
Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
Hoffmann-La Roche n=1,053
NCT04339413 TERMINATED
A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)
Hoffmann-La Roche n=116
NCT03443973 TERMINATED
Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
Hoffmann-La Roche n=975
NCT05665088 TERMINATED
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)
BioXcel Therapeutics Inc n=13
NCT04797715 COMPLETED
Assessing Clinical Outcomes in Alzheimer's Disease Agitation
Axsome Therapeutics, Inc. n=178
NCT03594123 COMPLETED
A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=259
NCT01872598 COMPLETED
Masitinib in Patients With Mild to Moderate Alzheimer's Disease
AB Science n=721
NCT03548584 COMPLETED
A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=345
NCT03226522 COMPLETED
Addressing Dementia Via Agitation-Centered Evaluation
Axsome Therapeutics, Inc. n=366
NCT03691519 COMPLETED
Prevention of Cognitive Decline in Older Adults With Low Dha/Epa Index in Red Blood Cells
University Hospital, Toulouse n=774
NCT01278407 COMPLETED
A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase
Eisai Co., Ltd. n=142
NCT01539031 COMPLETED
Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease
Eisai Co., Ltd. n=351
NCT02346201 COMPLETED
Apathy in Dementia Methylphenidate Trial 2
Johns Hopkins Bloomberg School of Public Health n=200
NCT02245568 TERMINATED
Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
TauRx Therapeutics Ltd n=913
NCT04187547 WITHDRAWN
A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension
Cerecin
NCT03823404 COMPLETED
GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease
Cortexyme Inc. n=643
NCT02442765 COMPLETED
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=387
NCT02051608 COMPLETED
A Study of Gantenerumab in Participants With Mild Alzheimer Disease
Hoffmann-La Roche n=389
NCT04520412 SUSPENDED
A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease
Green Valley (Shanghai) Pharmaceuticals Co., Ltd. n=2,046
NCT04623242 COMPLETED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
Washington University School of Medicine n=194
NCT02442778 COMPLETED
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=522
NCT01565382 COMPLETED
Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)
Avid Radiopharmaceuticals n=40
NCT03986424 COMPLETED
Local Study of Akatinol Memantine in VaD in Russia
Merz Pharmaceuticals GmbH n=130
NCT03790709 COMPLETED
ANAVEX2-73 for Treatment of Early Alzheimer's Disease
Anavex Life Sciences Corp. n=509
NCT03721705 COMPLETED
Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type
Renew Research, LLC n=190
NCT03628391 TERMINATED
Haloperidol for Delirium in Adult Critically Ill Patients
Erasmus Medical Center n=142
NCT02913664 COMPLETED
Risk Reduction for Alzheimer's Disease
University of Texas Southwestern Medical Center n=513
NCT02164643 COMPLETED
Longitudinal Study of Brain Amyloid imaGing in MEMENTO
University Hospital, Bordeaux n=448
NCT01224106 COMPLETED
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Hoffmann-La Roche n=799
NCT02547818 COMPLETED
Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease
AZTherapies, Inc. n=620
NCT02484547 TERMINATED
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
Biogen n=1,643
NCT02477800 TERMINATED
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
Biogen n=1,653
NCT03131453 TERMINATED
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
Novartis Pharmaceuticals n=1,145
NCT01741194 COMPLETED
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Cerecin n=418
NCT00951834 COMPLETED
Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease
Charite University, Berlin, Germany n=21
NCT02565511 TERMINATED
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
Novartis Pharmaceuticals n=480
NCT02817906 TERMINATED
ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease
Intra-Cellular Therapies, Inc. n=177
NCT03325556 COMPLETED
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
ACADIA Pharmaceuticals Inc. n=392
NCT02916056 TERMINATED
2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)
vTv Therapeutics n=297
NCT02080364 TERMINATED
Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
vTv Therapeutics n=880
NCT03785067 TERMINATED
Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study
The George Institute n=1
NCT03815292 COMPLETED
Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke
Materia Medica Holding n=276
NCT03197740 COMPLETED
A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease
Icure Pharmaceutical Inc. n=399
NCT02956486 TERMINATED
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
Eisai Co., Ltd. n=2,212
NCT01862640 COMPLETED
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
Otsuka Pharmaceutical Development & Commercialization, Inc. n=433
NCT01922258 COMPLETED
Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=270
NCT03075241 COMPLETED
Z-Drugs for Sleep Disorders in Alzheimer's Disease
Brasilia University Hospital n=62
NCT02248636 COMPLETED
Cholinesterase Inhibitor Discontinuation
VA Office of Research and Development n=72
NCT02016560 COMPLETED
Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects
Avid Radiopharmaceuticals n=383
NCT03901092 COMPLETED
A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation
Avid Radiopharmaceuticals n=242
NCT03901105 COMPLETED
Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease
Avid Radiopharmaceuticals n=205
NCT02670083 TERMINATED
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).
Hoffmann-La Roche n=813
NCT03114657 TERMINATED
A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
Hoffmann-La Roche n=806
NCT03491150 TERMINATED
An Open-Label Crenezumab Study in Participants With Alzheimer's Disease
Hoffmann-La Roche n=149
NCT02351882 COMPLETED
Safety and Efficacy of Nabilone in Alzheimer's Disease
Sunnybrook Health Sciences Centre n=38
NCT02350127 COMPLETED
Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia
VA Office of Research and Development n=88
NCT02586909 TERMINATED
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
Axovant Sciences Ltd. n=1,099
NCT04318639 COMPLETED
The Combination of Donepezil and Cognitive Training for Treating Alcohol Use Disorder
VA Connecticut Healthcare System n=15
NCT04301466 COMPLETED
Efficacy and Safety of Qi Zhi Tong Luo Capsule in Vascular Cognitive Impairment
Dongzhimen Hospital, Beijing n=362
NCT02353949 TERMINATED
Investigating the Clinical Consequences of Flutemetamol-PET-scanning
University of Zurich n=11
NCT02453932 COMPLETED
Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia
Dongzhimen Hospital, Beijing n=543
NCT02783573 TERMINATED
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
AstraZeneca n=1,722
NCT02972658 TERMINATED
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
AstraZeneca n=421
NCT02750306 COMPLETED
Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)
Merck Sharp & Dohme LLC n=285
NCT02760602 TERMINATED
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
Eli Lilly and Company n=26
NCT01900665 TERMINATED
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Eli Lilly and Company n=2,129
NCT01127633 TERMINATED
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Eli Lilly and Company n=1,457
NCT01931566 TERMINATED
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
Takeda n=3,494
NCT01561053 COMPLETED
A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease
Instituto Grifols, S.A. n=347
NCT02284906 TERMINATED
AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease
Takeda n=40
NCT03542656 COMPLETED
Application of Amyloid PET in Cerebral Amyloid Angiopathy
National Taiwan University Hospital n=160
NCT01953601 TERMINATED
Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)
Merck Sharp & Dohme LLC n=1,454
NCT03010865 WITHDRAWN
Sodium Butyrate For Improving Cognitive Function In Schizophrenia
Shanghai Mental Health Center
NCT01299766 COMPLETED
Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment
Thomas Jefferson University n=221
NCT00838110 COMPLETED
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
Pfizer n=742
NCT02585934 COMPLETED
Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study
Axovant Sciences Ltd. n=1,315
NCT01739348 TERMINATED
An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)
Merck Sharp & Dohme LLC n=2,211
NCT02317250 WITHDRAWN
Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II
University of California, Los Angeles
NCT02293915 COMPLETED
An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease
Shanghai Greenvalley Pharmaceutical Co., Ltd. n=818
NCT02079246 COMPLETED
Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease
H. Lundbeck A/S n=1,463
NCT02550665 COMPLETED
Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg
Asan Medical Center n=176
NCT02928445 TERMINATED
Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension
Axovant Sciences Ltd. n=240
NCT01689233 COMPLETED
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
TauRx Therapeutics Ltd n=800
NCT01689246 COMPLETED
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
TauRx Therapeutics Ltd n=891
NCT01626378 COMPLETED
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
TauRx Therapeutics Ltd n=220
NCT02374567 TERMINATED
Pharmacovigilance in Gerontopsychiatric Patients
Hannover Medical School n=407
NCT01670526 COMPLETED
Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI
VA Office of Research and Development n=94
NCT02006641 COMPLETED
Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil
H. Lundbeck A/S n=858
NCT02006654 COMPLETED
Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor
H. Lundbeck A/S n=734
NCT02168920 TERMINATED
Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Co., Ltd. n=150
NCT01955161 COMPLETED
Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil
H. Lundbeck A/S n=933
NCT01219244 COMPLETED
Effects of Dietary Interventions on the Brain in Mild Cognitive Impairment (MCI)
Charite University, Berlin, Germany n=330
NCT01047254 COMPLETED
Bupropion for the Treatment of Apathy in Alzheimer's Dementia
University Hospital, Bonn n=110
NCT01973400 COMPLETED
Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus
Universiti Sains Malaysia n=300
NCT01883648 TERMINATED
Study to Evaluate Coconut Oil for Alzheimer's Disease
University of South Florida n=21
NCT02035982 COMPLETED
Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease
Sunnybrook Health Sciences Centre n=40
NCT01404169 COMPLETED
A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease
Eisai Limited n=260
NCT02017340 COMPLETED
A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease
Prof Brian Lawlor n=511
NCT00675623 COMPLETED
A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease
Medivation, Inc. n=598
NCT00829374 COMPLETED
Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
Medivation, Inc. n=1,003
NCT01409694 COMPLETED
Alzheimer's Disease - Input of Vitamin D With mEmantine Assay
University Hospital, Angers n=90
NCT01614886 COMPLETED
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Novartis Pharmaceuticals n=216
NCT01325714 COMPLETED
Preventing Aggression in Veterans With Dementia
VA Office of Research and Development n=203
NCT00676143 TERMINATED
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
Pfizer n=1,100
NCT01020838 COMPLETED
Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology
Life Molecular Imaging SA n=218
NCT01577394 COMPLETED
Oculomotor Testing in the Differential Diagnosis of Dementia
Assistance Publique - Hôpitaux de Paris n=65
NCT01969136 TERMINATED
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
FORUM Pharmaceuticals Inc n=403
NCT01969123 TERMINATED
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
FORUM Pharmaceuticals Inc n=474
NCT02004392 TERMINATED
Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025
FORUM Pharmaceuticals Inc n=348
NCT01688128 COMPLETED
Efficacy of Ubiquitous SR-based Memory Advancement and Rehabilitation Training (U-SMART)
Seoul National University Bundang Hospital n=50
NCT01582854 COMPLETED
Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)
Takeda n=503
NCT00667810 TERMINATED
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
Pfizer n=901
NCT00998764 TERMINATED
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
Pfizer n=494
NCT01194128 COMPLETED
Facilitating Caregiver Adaptation to Patient Institutionalization
University of Pittsburgh n=217
NCT02327182 TERMINATED
Safety Study of MT-4666 in Subjects With Alzheimer's Disease
Tanabe Pharma Corporation n=117
NCT00743743 WITHDRAWN
Pilot Study of the Effects of Resveratrol Supplement in Mild-to-moderate Alzheimer's Disease
Medical College of Wisconsin
NCT02099890 COMPLETED
The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury
Brock University n=20
NCT02350738 COMPLETED
Effects of Multimodal Cognitive Enhancement Therapy (MCET) for Ealy Dementia
Ki Woong Kim n=64
NCT01667484 COMPLETED
Adderall XR and Processing Speed in Multiple Sclerosis (MS)
London Health Sciences Centre n=70
NCT00908492 COMPLETED
Supporting Caregivers of Persons With Dementia: A Pilot Study
McMaster University n=38
NCT00594568 COMPLETED
Effect of LY450139 on the Long Term Progression of Alzheimer's Disease
Eli Lilly and Company n=1,537
NCT00762411 COMPLETED
Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo
Eli Lilly and Company n=1,111
NCT01681602 COMPLETED
Effect of Physical Exercise in Alzheimer Patients
Rigshospitalet, Denmark n=200
NCT01451749 COMPLETED
Efficacy and Safety Study of Shenwu Capsule
North China Pharmaceutical Group Corporation n=324
NCT01028053 COMPLETED
Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
GE Healthcare n=365
NCT01399125 COMPLETED
A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
Novartis Pharmaceuticals n=501
NCT00898807 COMPLETED
Citalopram for Agitation in Alzheimer's Disease
JHSPH Center for Clinical Trials n=186
NCT01672827 COMPLETED
Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images
GE Healthcare n=276
NCT00996918 TERMINATED
A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients
Pfizer n=198
NCT00937352 TERMINATED
A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
JANSSEN Alzheimer Immunotherapy Research & Development, LLC n=896
NCT01249196 COMPLETED
A Confirmatory Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease
SK Chemicals Co., Ltd. n=256
NCT01662882 COMPLETED
A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Avid Radiopharmaceuticals n=48
NCT00679627 TERMINATED
A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease
Janssen Research & Development, LLC n=2,051
NCT00646269 COMPLETED
Efficacy Assessment of Three Non Pharmacological Therapies in Alzheimer's Disease
University Hospital, Bordeaux n=640
NCT00804271 COMPLETED
Memantine and Validation of a New Alzheimer's Disease Scale
Merz Pharmaceuticals GmbH n=487
NCT00904683 COMPLETED
Effect of LY2062430 on the Progression of Alzheimer's Disease
Eli Lilly and Company n=1,040
NCT00678431 COMPLETED
Randomized Trial of a Nutritional Supplement in Alzheimer's Disease
US Department of Veterans Affairs n=27
NCT00939783 TERMINATED
An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease
Pfizer n=649
NCT01142258 COMPLETED
Trazodone for Sleep Disorders in Alzheimer's Disease
Brasilia University Hospital n=40
NCT00912288 TERMINATED
A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease
Pfizer n=86
NCT01066546 TERMINATED
An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease
Pfizer n=5
NCT00905372 COMPLETED
Effect of LY2062430 on the Progression of Alzheimer's Disease
Eli Lilly and Company n=1,000
NCT00857415 COMPLETED
Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain
Avid Radiopharmaceuticals n=226
NCT00767091 COMPLETED
Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia
University Hospital, Lille n=40
NCT01183806 COMPLETED
Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients
Federal University of Bahia n=40
NCT01021696 COMPLETED
Pain in Patients With Dementia and Behavioural Disturbances
University of Bergen n=352
NCT01245530 COMPLETED
An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia
Whanin Pharmaceutical Company n=280
NCT00622128 COMPLETED
Preventing Aggressive Behavior in Demented Patients
US Department of Veterans Affairs n=10
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only